Harvard Apparatus Regenerative Tech Inc  

(Public, NASDAQ:HART)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
8.70
0.00 (0.00%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.00 - 11.89
Open     -
Vol / Avg. 0.00/392,707.00
Mkt cap 67.88M
P/E     -
Div/yield     -
EPS -1.14
Shares 7.80M
Beta     -
Inst. own 45%

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -12036.36% -40077.27%
Operating margin -12036.36% -40077.27%
EBITD margin - -39359.09%
Return on average assets -136.54% -113.75%
Return on average equity -144.67% -120.81%
Employees 20 -
CDP Score - -

Address

84 October Hill Road
HOLLISTON, MA 01746
United States - Map
+1-774-2337300 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Harvard Apparatus Regenerative Technology, Inc. is clinical stage regenerative medicine company developing life-saving medical devices. The Company�s products include Hollow Organ Bioreactors, Solid Organ Bioreactors, Scaffolds, and Clinical Infusion Pump. The Company�s first products are a bioreactor and a synthetic scaffold that can be used by surgeons to create a replacement trachea, or airway, for patients who need an airway transplant. Its bioreactor technology has been used in six human airway transplant surgeries. Its r products are in development. The Company�s products address the critical challenges to trachea transplant, the shortage of suitable donor tracheas. The Company is a wholly owned subsidiary Harvard Bioscience Inc. In October 2013, Harvard Bioscience Inc announced the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc.

Officers and directors

David M. Green Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Chane Graziano Director
Bio & Compensation  - Reuters
John F. Kennedy Independent Director
Age: 64
Bio & Compensation  - Reuters
James J. McGorry Independent Director
Age: 56
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 54
Bio & Compensation  - Reuters